Clinical Study
Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
Table 1
Efficacy analyses—pooled data from ADAPT-1 and ADAPT-2 (full analysis set).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CI = Confidence interval, Max = maximum, Min = minimum, SD = standard deviation. †Responders are defined as the subjects not requiring a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure; two-sided 95% confidence interval based on normal approximation. -value is based on Cochran–Mantel–Haenszel Test stratified by the risk of bleeding associated with the scheduled procedure within each Baseline platelet count cohort. ‡Responders are defined as the subjects who achieved platelet count ≥50 × 109/L on the Procedure Day. §Last-observation-carried-forward is used for subjects with missing platelet count on the Procedure Day. -value is based on Wilcoxon Rank Sum Test for each avatrombopag treatment group versus placebo within each Baseline platelet count cohort. |